Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune vulnerabilities of mutant KRAS in pancreatic cancer.

Trends in cancer - 1 Nov 2023

Cheng Noah C, Vonderheide Robert H

Abstract excerpt

The 40-year desire to target the mutant Kirsten rat sarcoma (KRAS) gene (mKRAS) therapeutically is being realized with more and more broadly applicable and tumor-specific small-molecule inhibitors. Immunologically, mKRAS has equal desirability as a target. Tumor KRAS signaling plays a large role in shaping the immunosuppressive nature of the tumor microenvironment, especially in pancreatic cancer, leaving mKRAS...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Mutation
Share to Pancreatic Neoplasms
Share to Proto-Oncogene Proteins p21(ras)

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Signal Transduction

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 37524642
DOI: 10.1016/j.trecan.2023.07.004
PMCID: PMC10592263

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune vulnerabilities of mutant KRAS in pancreatic cancer.PMID 37524642Read ↗

Facts and Hopes in Immunotherapy Strategies Targeting Antigens Derived from KRAS Mutations.Semantic proximity Read ↗

Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting.Semantic proximity Read ↗

Targeting KRAS in colorectal cancer immunotherapy: rationale, challenges and future directions.Semantic proximity Read ↗

Current advances in immunotherapy for KRAS-Mutant pancreatic cancer.Semantic proximity Read ↗

An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancer.Semantic proximity Read ↗

Unveiling the role of KRAS in tumor immune microenvironment.Semantic proximity Read ↗

Exploiting the therapeutic implications of KRAS inhibition on tumor immunity.Semantic proximity Read ↗

Oncogenic dependency plays a dominant role in the immune response to cancer.Semantic proximity Read ↗

Immune modulatory effects of oncogenic KRAS in cancerSemantic proximity Read ↗

Chimeric Antigen Receptors Directed at Mutant KRAS Exhibit an Inverse Relationship Between Functional Potency and Neoantigen SelectivitySemantic proximity Read ↗

Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.Semantic proximity Read ↗

Cancer vaccines: Targeting KRAS-driven cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.